Who are Higher-volume C1-esterase inhibitor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Low-volume C1-esterase inhibitor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/higher-volume-c1-esterase-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Higher-volume C1-esterase inhibitor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Higher-volume C1-esterase inhibitor (Higher-volume C1-esterase inhibitor) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serine protease inhibitor / Complement regulator. Area: Immunology / Rare Disease.

phase 3 Serine protease inhibitor / Complement regulator C1-esterase (C1s), Factor XIIa, Plasma kallikrein Immunology / Rare Disease Biologic Live · refreshed every 30 min

Target snapshot

Higher-volume C1-esterase inhibitor (Higher-volume C1-esterase inhibitor) — CSL Behring. A higher-concentration formulation of C1-esterase inhibitor that suppresses activation of the contact system and complement cascade to prevent angioedema attacks.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Higher-volume C1-esterase inhibitor TARGET	Higher-volume C1-esterase inhibitor	CSL Behring	phase 3	Serine protease inhibitor / Complement regulator	C1-esterase (C1s), Factor XIIa, Plasma kallikrein
Low-volume C1-esterase inhibitor	Low-volume C1-esterase inhibitor	CSL Behring	phase 3	Serine protease inhibitor / Complement regulator	C1-esterase inhibitor (C1-INH protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serine protease inhibitor / Complement regulator class)

CSL Behring · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Higher-volume C1-esterase inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/higher-volume-c1-esterase-inhibitor. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab